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ABSTRACT
Big data analysis has enhanced its demand nowadays in various sectors of health-care including pharmacovigilance. The exact definition of big data 
is not known to many people though it is routinely used by them. Big data refer to immense and voluminous computerized medical information 
which are obtained from electronic health records, administrative data, registries related to disease, drug monitoring, etc. This data are usually 
collected from doctors and pharmacists in a health-care facility. Analysis of big data in pharmacovigilance is useful for early raising of safety alerts, 
line listing them for signal detection of drugs and vaccines, and also for their validation. The present paper is intended to discuss big data analytics in 
pharmacovigilance focusing on global prospect and domestic country-India.
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INTRODUCTION
Big data is marked and cited as keyword nowadays in various sectors 
of health care including pharmacovigilance (Pv). The exact definition 
of big data is not known to many people though it is routinely used 
by them. An illustrious definition of big data relates to enormous data 
which are generated and are readily available for use. Increasing data 
availability along with technological advances provide new possibilities 
to store, mine, and analyze data across multiple data sources.
Big data refer to immense and voluminous computerized medical 
information which are obtained from electronic health records, 
administrative data, registries related to disease and drug monitoring 
[1]. This data is usually collected from doctors and pharmacists in a 
health care facility. However, the main drawback of this data is that its 
correctness has to be checked as there may be some inter-related issues 
such as duplications and so on [1]. In ancient times, data was collected, 
written, and stored in the form of records (Table 1). As time passed, 
these records were damaged and the information about the healthcare 
events was not available. With the advent of big data in health-care 
facility every known information is stored in a database and is made 
available for use. Despite its availability, for a long time, the true use 
of big data for analysis is popularized in recent times. The use of big 
data analytics was started increasing in Europe, America, and recently 
in Asia.
Pv involving adverse drug events (ADEs) and adverse drug reactions 
(ADRs) became the knowledge of interest with the evolution of new 
drugs and vaccines by various pharmaceutical companies. Moreover, 
manual recording of all these events and reactions was a difficult and 
troublesome task. The introduction of big data analysis in Pv bridged 
all the gaps to the regulatory authorities, pharmaceutical companies, 
and researchers by providing all relevant information related to data 
collection, assessment of ADE/reaction, signal detection, and validation.
This article gives an overview concept of present big data mining 
methods, approaches, applications, and limitations along with ethical 
considerations and future prospects in Pv.
SOURCE OF INFORMATION AND SEARCH STRATEGY FOR 
IDENTIFYING RELEVANT LITERATURE:
To ensure a comprehensive research review of the study, search terms 
were carried out using key text words as “Big Data,” “Data Analytics,” 
“Data Mining,” “Real and Smart Data,” “Drug safety,” and “Pv.” These 
terms were used individually and in combination to sew up for widening 
the search window of the literature collection. Relevant published 
articles from data bases such as “PubMed, Medline, and SCOPUS,” were 
selected for disusing the objective of the review.
BIG DATA IN PV
Big data is used in Pv to analyze the large electronic information about 
ADEs/reactions which may be structured or unstructured in spontaneous 
reporting system databases and other databases [2]. Post-marketing 
surveillance of drug safety is mainly reviewed by systematic analysis 
of spontaneous reporting system database [3] (Table 2). Vigiflow-UMC, 
ADRMS (in developing stage), Safe-Vac for AEFIs in India, Eudra-vigilance 
in the European Union and FAERS (FDA Adverse Event Reporting System) 
in the United States, and JADER (Japanese ADE Report) in Japan are few 
spontaneous reporting system databases in Pv [4]. Vigibase is the global 
Pv monitoring database maintained and monitored by the World Health 
Organization-Uppsala Monitoring Centre located in Sweden [5].
HOPE, HYPE, AND REALITY OF BIG DATA IN PV
The hope and much of the hype of big data for Pv center on new data 
streams and technologies as a source for identifying potential new safety 
signals [6]. Electronic health records are also one of the big data used 
in Pv. Other big data used in Pv include databases of hospital discharge, 
out-patient diagnostic tests, laboratory test findings, emergency 
department, pediatrics and geriatric assessment records, mortality, 
and disease registries [7]. Social media is also used to promote Pv. This 
media uses text mining and is in the stage of development [8]. Using 
social media such as Twitter or Facebook, several patients share their 
personal experiences related to drug therapy and provide a good source 
for early signal detection [9].
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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Review Article
20
Asian J Pharm Clin Res, Vol 14, Issue 10, 2021, 19-24
 Aitha et al.
All this computerized electronic information is processed and assessed for 
signal detection of various ADRs [10] (Fig. 1). Signal detection is the process 
of actively searching and identifying safety information about ADRs from a 
wide variety of data sources [11]. Data mining is one of the common data 
analysis methods for signal detection. Other common methods include 
Geographic Information systems (GIS), Text and information mining 
(ADETM), and Visualization tools [12]. Among the various statistical 
techniques covered in data mining Pv analytics will use the following:
•	 Descriptive modeling: This method is used to uncover shared 
similarities or grouping in historical data to determine reasons 
behind success or failure. Techniques belonging to this group include 
clustering, anomaly outlier detection, association rule learning, 
principal component analysis, and affinity grouping [12]
•	 Predictive modeling: This method is used to classify events in the 
future or estimate unknown outcomes. Techniques belonging to this 
group include regression, artificial neural networks, decision trees, 
random forest, and support vector machines [12]
•	 Prescriptive modeling: This method is also called the last frontier 
of analytic capabilities. It takes information from descriptive and 
predictive analytics and combines it with information obtained from 
unstructured data for improved prediction accuracy [12]
•	 Disproportionality methods: This method is used to identify the 
statistical association between products and events. These methods 
compare the observed count for product-event combination with an 
expected count [12].
Many data mining software are commercially available for Pv such as 
Empirica Signal, PV-Analyzer, SAS (Statistical Analysis System), and 
Molecular Analysis of Side Effects [13]. In the United States, Patient-
Centered Outcome Research Network data system is used. Similar 
networks for patient safety have been developed around the world: Asian 
Pharmacoepidemiology Network in Asia [14] and Canadian Network 
for Observational Drug Effect Studies in Canada [15]. Networks such as 
Observational Medical Outcomes Partnership and Observational Health 
Data Sciences and Informatics, primarily focus on method testing 
and informatics tool development for data networks [16]. The joint 
International Society of Pharmacoepidemiology-International Society 
of Pharmacoeconomics and Outcomes Research taskforce on Real-
World Evidence in health-care decision-making guides on the design 
and reporting of Pharmacoepidemiologic analyzes of longitudinal 
health-care databases [17-19].
All the above methods of big data analysis are used in various domains 
of Pv such as quality management, risk management, management of 
ICSRs, aggregate reporting, and signal management. These methods 
have demonstrated their promise in enhancing multiple areas of 
disease management, population health, and precision medicine. 
These augment clinical-decision making in healthcare. In the coming 
years, ongoing initiatives, such as the IMI’s [26] WEB-RADR, and 
the Exponential Moving Average’s goal to measure the impact of Pv 
practices, will identify the best uses of these data methods for Pv, along 
with patient populations, outcomes, or medicines that are best suited 
for signal detection. The outcome of any contribution of big data to 
Pv practice critically evaluates the impact of innovative data sources, 
techniques and whether these should uniquely complement or replace 
existing approaches, or are redundant, adding little, or no value to 
current Pv practice.
ROLE OF REAL-WORLD DATA IN THE ANALYSIS OF BIG DATA IN PV
Real-world data can include any information that is generated from 
the patient’s records while admitted to the hospital and is treated to 
be the first resource when building predictive models. This data can 
also be generated from registries and pharmaceutical trials that the 
patient is undergoing for treatment or clinical trial studies. A well-
collected repository of real-world data aids in accumulating enough 
weight for real-world evidence. Real-world evidence is to be considered 
for validating the big data models that are created to confirm their 
usefulness in Pv [27].
APPROACH TO BIG DATA IN PV
The big data approach to Pv [28] is performed in a systematic manner 
involving the following steps:
•	 Characterize relevant sources of big data and define the main format 
in which they can be expected to exist in
•	 Identify areas of usability and applicability of data
•	 Describe the current status of expertise, future needs, and challenges 
by gap analysis
•	 Generate a big data roadmap and list of recommendations.
The above steps will enhance the best way to analyze big data with 
accuracy by reducing manual errors and the time required for 
analysis [28]. Fig 2 depicts that relevant sources of big data may be 
derived from the web and social media (Facebook, Twitter, LinkedIn, 
Google, and WhatsApp), health-care databases in domestic country 
India (SOCH for HIV, Nikshay & Aarogyasethi for TB, and Cowin for 
COVID-19) are linked to drug safety information (PvPI-Pv Program 
of India, CDSCO-Central Drug Standard Control Organization, WHO-
World Health Organization, and Safe-vac for adverse events following 
immunization [AEFI]). Processing and analysis are done using various 
IT tools [12] in big data such as Hadoop, R, STATA [27], Hbase, and 
Cassandra. Hadoop tool is mainly used to store, process, and analyze big 
data sets. Cassandra tool provides high availability and scalability. STATA 
explores the relationship between unstructured text to structured data 
using quantitative and qualitative methods [27]. After data collection 
and linkage from the above mentioned sources followed by processing 
and analysis Pv safety measures are implemented through education 
on safety use of medicines to patients, caution on prevention of ADRs/
ADE from the regulatory agency is provided to health-care professional 
(HCPs) and patients, early detection of ADRs/ADEs and prediction of 
ADR occurrence. The advantage of linking data collection databases 
and records as mentioned above will help to analyze the proposed 
metrics applicable to all AEs detection, prediction and highlighting the 
designated medical events, and targeted medical events. These ICSR 
metrics are pooled using the MedDRA for medical coding of adverse 
events, WHO-DD for drugs and causality scale for causality assessment 
and expectedness from labels and literature, severity from severity 
scoring scales, and outcome of related reported events [27]. All these 
summarizing together with big data pooling would act as indicators 
for HCPs in implementation of early detection and prevention of AE(s) 
as triggering tools for patient safety in public health system either 
in domestic country (India) or globally. Big data offer BDD concept 
of “Breath, Depth, and Diversity.” Breath includes large number of 
individuals making closer to the underlying source population with 
reduction in selection bias, depth relates to the increasing amount of 
data on each individual increases the chance that might have measures 
of likely confounders with potential reduction in information bias, and 
diversity relates to the various types of data that offer the potential to 
cross refer finding for any particular data source from datasets with 
significance to enhance control for residual bias [27,28].
USFDA also proposed a new surveillance program within its office of 
“Clinical Pharmacology (OCP)” which is known as “Pharmacological 
Mechanism-Based Drug Safety Prediction (PMDSP) [29]” program 
which uses the big data analysis to analyze the data sets of AEs reported 
and raises the safety alerts and communicates to the stakeholders to 
line list them for monitoring, reporting, and signal implementation for 
patient safety with the help of predictive tools [29]. PMDSP along with 
center for drug evaluation and research used the real-world evidence 
Fig. 1: Data mining using big data in
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data to monitor and evaluate the safety of drug products after they 
are approved (post-market). Examples of such safety evaluation of 
real world data using large data sets of USFDA are risk of stroke after 
using antipsychotics, risk of seizures after using ranolazine, and risk 
of venous thromboembolism after an extended or continuous cycle 
of oral contraceptives. Similarly, it has also launched other program 
in connection with the Center for Biologics Evaluation and Research 
(CBER) focusing surveillance efforts within the sentinel system for 
vaccine safety, using the Post-Licensure Market Rapid immunization 
safety Monitoring (PRISM) system, for blood components with blood 
surveillance continuous active surveillance network (BloodSCAN) 
and initiated “Biologics Effectiveness and Safety (BEST)” [30] project 
to assure the safety and effectiveness of biologic products including 
vaccines, blood and blood products, human tissues, cellular products, 
gene therapies, allergenics, xenotransplantation products, and devices 
related to biologics. Specially, it is using the BEST project to evaluate the 
large volumes of data sets in connection with rates of adverse events 
of special interest (AESI) for COVID-19 vaccine safety surveillance and 
monitoring. The project according with “CBER-BEST” was to mine data 
and recognize patterns through the use of technology to find as yet 
unrecognized safety signals after emergency use approval of COVID-19 
vaccines and implement the benefit-risk plan [30].
APPLICATIONS OF BIG DATA ANALYTICS IN PV
Big data analysis performs safety assessments, comparative 
effectiveness studies, and investigational trials in a real-world setting. 
The following are the various applications of big data analytics in Pv:
•	 Pre-marketing drug safety surveillance: Big data analysis is used 
to analyze reports, improve the identification process, and layout 
potential safety issues. Recent methods of big data analytics are 
also proved to be useful in research. Data mining saves time by the 
implementation of automated standardization of data, statistical 
scores, and prioritization of signals and also helps in understanding 
the biological basis for signals [31]
•	 Post-marketing safety surveillance: Pharmaceutical industries use 
big data analytics in identifying drug safety signals earlier, assessing 
risk, and interpreting clinical trial results [32]. Big data analytics save 
Table 1: Various safety reporting system databases





Fig. 2: Systematic approach to big data in pharmacovigilance
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a great deal of time, money, and logistically helps the pharmaceutical 
industry in assessing signals in large volumes of data sets
•	 Regulatory decision making: Regulatory agencies rely on big data 
analytics for the identification of signals in cases of ADR and also in 
vaccine vigilance. Once a signal is detected using big data analysis, 
regulatory agencies make decisions concerning the implementation 
of signals as label changes, and benefit-risk monitoring of drugs [33]
•	 Clinical practice: In clinical practice, this analysis provides 
information on the disease, previous consultations, diagnostics, 
test results, and treatment. The blood type, allergies, diseases, 
possible medications, and vital signs measurement, everything are 
centralized and can be searched at a glance. Using big data analytics 
in daily practice, correct information can be provided quickly in case 
of emergency
•	 Clinical trials: Advanced analytics can create value in clinical trials 
in the following ways:
• Improved data quality by analyzing different kinds of data 
through automation
• Efficient data mining by identifying deviations, differences, and 
improving transparency
• Data-driven decision-making through corrective and preventive 
measures of data exploration.
Achievements of big data in Pv
•	 Danish and Swedish medical birth registries were used to study the 
prevalence of congenital malformations among infants exposed and 
not exposed to varenicline in utero by linkage to nationwide registries 
of dispensed prescriptions and hospital admissions [34]
•	 In the United States, the safety of meningitis B vaccination that is 
Trumenba vaccine exposure during pregnancy was studied using 
electronic health-care data and linked birth certificates from multiple 
health-care systems [35]
•	 In the United Kingdom, the researchers used smartphones and linked 
mobile data to study the relationship between weather patterns and 
rheumatoid arthritis symptoms. This study collects data about the 
severity of pain symptoms from an app and then links it to weather 
information based on the patient’s location at the time of data 
entry [36]
•	 Pharmacoepidemiology research in the use of consumer wearable 
technology is gaining importance nowadays. These data streams 
and networks of sensors focus on medical and behavioral data such 
as heart rate, smoking status, alcohol consumption, and exercise 
pattern to examine relationships between data types previously 
unknown [37].
RECENT APPLICATIONS OF BIG DATA ANALYTICS IN PV
•	 COVID-19 drugs and vaccines
 In COVID-19 pandemic, Pv analysis using big data plays a key 
role in reducing false information and providing correct data 
and explanations to patients about drug usage [38]. This analysis 
generates valuable information about a disease such as hidden 
patterns, unknown trends, correlations, and patient preferences.
 Key applications of Pv analytics in COVID-19 include the following:
• Enhanced drug and vaccine safety and faster compliance
• Benefit-risk analysis
• Better protection for patients.
Big data analysis using data mining tools help to detect the new and 
unknown AEFI and AESI in subpopulation that is not adequately 
studied or excluded from trails, so continuity to monitor the safety 
concerns of these vaccines once they are rolled out with emergency 
use approval in connection to COVID-19 is on huge demand. Automated 
signals detected masking the noise of the background raised with the 
help of big data sets could be beneficial in analyzing the risk.
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Fig. 3: Big data mining in pharmacovigilance-hospital setup
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•	 Orphan drugs
 In the past treatment of rare diseases was a challenge and there 
was little interest to develop new medicines for these diseases 
due to fewer market incentives. Since the number of people using 
orphan drugs is very small, it is difficult to conduct Pv. To solve 
this issue, patient support programs were established that help to 
produce safety reports too [39]. Analysis of these reports is of great 
importance in the Pv of orphan drugs.
DATA PRIVACY OF BIG DATA ANALYTICS IN PV
Data privacy is an important issue whenever the information is posted 
and allowing easy access for use of this data in research. The user is 
responsible for preserving the anonymity of information about the 
patient’s identity. There are still ethical issues in using social media for 
the evaluation of new medical knowledge, the most important being each 
patient to be guaranteed to keep his anonymity. Current principles and 
guidelines for protecting individual’s privacy rights lack technological 
developments. Procedures were designed to guarantee that the only 
data going through a step of data minimization should be accessible for 
analysis by registered end users, but the raw data were kept accessible 
in very specific circumstances to allow contacting the patient if drug 
withdrawal was required for safety reasons. Concerning privacy and 
confidentiality, much work is needed in terms of formulating guidelines 
to help drug developers understand the nature and extent of big data 
that would be deemed admissible in the drug approval process [40,41].
LIMITATIONS OF BIG DATA ANALYTICS IN PV
Despite big data play a major role in various sectors of Pv, there are 
certain limitations. These limitations include paucity of established 
standards and validation methods, bias, false signals, confounding 
variables, and data inconsistencies [42]. Available data which are 
incorrect, missing, or duplicate are another major challenge faced in big 
data analytics. Poor quality data algorithms may not be well understood 
by decision-makers to make inferences about particular signal detection. 
In India, the major challenge is faced mainly when patient’s care may 
be documented in more than one electronic health record if they seek 
care at different institutions or practices leading to large amount of 
unstructured data and structured data might not substantially augment 
administrative data. Prescription versus dispensing challenges are also 
observed due to varied patient preferences.
LEGAL AND ETHICAL CONSIDERATIONS OF BIG DATA ANALYTICS 
IN PV
Legal considerations
Legal aspects in big data analysis are considered in terms of reporting. 
Reporting in Pv is performed through adverse event case reports, health 
agency databases (Vigibase, and FAERS), data from cohort studies, 
published literature, social media, and so on. These reports allow 
regulatory agencies to inquire into health records, electronic medical 
records, registries, and safety issues.
Ethical considerations [43]: Ethical aspects to be ensured while dealing 
with big data analysis in Pv include the following;
•	 Generating qualitative data of ADRs and their related treatment
•	 Transparency in maintaining and reporting ADRs
•	 Anticipate decision-making in the case of signal detection
•	 Establishment of risk-benefit profile based on the analysis of available 
data
•	 Identification of high-risk vulnerable populations.
FUTURE PERSPECTIVE OF BIG DATA ANALYTICS IN PV
Big data can identify correlations of patients’ information within diverse 
datasets. Future directions which will overcome the current limitations 
of big data analytics in Pv include improvement inconsistency among 
data sources, validation of utilizing data sources, the establishment of 
standards for signal detection, application of an integrative approach 
to signal detection, improvement of data mining software and tools, 
application of data mining to other product safety and regulatory 
issues [44].
CONCLUSION
Big data analytics has been successful in identifying new drug-related 
ADE/ADR for drug safety surveillance purposes. Although numerous 
challenges remain, the opportunity for big data to make further 
contributions to Pv efforts is evident. Improved methods, tools, and 
data sources used in drug safety surveillance are still in the early stages 
of development and are likely to further advance the use of big data in 
Pv. Finally, how well big data improve the detection of drug safety issues 
will be the true measure of its value.
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